Cellectis CLLS
NASDAQ CLLS
$1.43 +0.03 (+2.14%)
At close: Oct 2, 2026 · 4:00 PM EDT

Cellectis (CLLS) Income from Discontinued Operations (2021 - 2023)

Updated

Cellectis' Income from Discontinued Operations was $8.39 million in FY2023, compared with -$15.35 million in FY2022.

Analysis

Cellectis (CLLS) Income from Discontinued Operations (2021 - 2023) Analysis & Trends

From FY2013 onward, Cellectis has reported Income from Discontinued Operations for 9 years.

  • The FY2023 figure marks the highest annual Income from Discontinued Operations since FY2017.
  • Per Business Quant data, Income from Discontinued Operations in earlier years was -$15.35 million in FY2022, -$28.36 million in FY2021 and -$43.9 million in FY2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Discontinued) (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn -
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn -
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn -
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn -
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn -
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 8.00 Mn
10 Cellectis 143.49 Mn -609.91 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 13.08 Mn
Mar 31, 2023 -4.69 Mn
Dec 31, 2022 -2.86 Mn
Sep 30, 2022 -5.72 Mn
Jun 30, 2022 -442,000.00
Mar 31, 2022 -6.44 Mn
Dec 31, 2021 -6.65 Mn
API Access

Cellectis Income from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-discontinued-operations&ticker=CLLS&period=max&api_key=YOUR_API_KEY